Obio Technology (Shanghai) Full Year 2023 Earnings: Misses Expectations

Obio Technology (Shanghai) (SHSE:688238) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥204.8m (down 30% from FY 2022).
• Net loss: CN¥127.9m (down by 428% from CN¥39.0m profit in FY 2022).
• CN¥0.20 loss per share (down from CN¥0.064 profit in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Obio Technology (Shanghai) Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 24%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.

Performance of the Chinese Life Sciences industry.

The company's shares are up 9.6% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Obio Technology (Shanghai)'s balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.